WO2007030012A3 - Extracellular matrix imaging - Google Patents

Extracellular matrix imaging Download PDF

Info

Publication number
WO2007030012A3
WO2007030012A3 PCT/NL2006/050217 NL2006050217W WO2007030012A3 WO 2007030012 A3 WO2007030012 A3 WO 2007030012A3 NL 2006050217 W NL2006050217 W NL 2006050217W WO 2007030012 A3 WO2007030012 A3 WO 2007030012A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
cellular matrix
extra cellular
imaging
matrix components
Prior art date
Application number
PCT/NL2006/050217
Other languages
French (fr)
Other versions
WO2007030012A2 (en
Inventor
Katherine Bell Nash Krahn
Maarten Merkx
Carolina Victoria Catha Bouten
Gustav J Strijkers
Original Assignee
Stichting Tech Wetenschapp
Univ Eindhoven Tech
Katherine Bell Nash Krahn
Maarten Merkx
Carolina Victoria Catha Bouten
Gustav J Strijkers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Tech Wetenschapp, Univ Eindhoven Tech, Katherine Bell Nash Krahn, Maarten Merkx, Carolina Victoria Catha Bouten, Gustav J Strijkers filed Critical Stichting Tech Wetenschapp
Publication of WO2007030012A2 publication Critical patent/WO2007030012A2/en
Publication of WO2007030012A3 publication Critical patent/WO2007030012A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to labelled conjugates, for example alpha 1 intergrin A-domain or collagen adhesin of S. aureus (CNA 35), for imaging extra cellular matrix components. It also relates to compositions and kits comprising these labelled conjugates and to imaging methods in which the conjugates are used. The conjugates of the invention comprise a peptide sequence which binds to an extra cellular matrix component, i.e. to an extra cellular matrix protein or to proteoglycans, and which is coupled to an imaging agent. In particular conjugates which bind to elastin, collagen or to a glycosaminoglycan are envisaged. The conjugates according to the invention have some important advantages over existing tools for imaging extra cellular matrix components, in particular for applications in tissue-engineering experiments or MRI. The use of protein conjugates of the invention allow visualization of very small extra cellular matrix components, such as newly formed collagen fibrils.
PCT/NL2006/050217 2005-09-05 2006-09-05 Extracellular matrix imaging WO2007030012A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05108103 2005-09-05
EP05108103.2 2005-09-05

Publications (2)

Publication Number Publication Date
WO2007030012A2 WO2007030012A2 (en) 2007-03-15
WO2007030012A3 true WO2007030012A3 (en) 2007-10-04

Family

ID=35561655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2006/050217 WO2007030012A2 (en) 2005-09-05 2006-09-05 Extracellular matrix imaging

Country Status (1)

Country Link
WO (1) WO2007030012A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124639A2 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
WO2014025392A1 (en) * 2012-08-09 2014-02-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for preparing biological specimens for microscopic analysis
JP2017509587A (en) 2013-12-27 2017-04-06 ノーバス・インターナショナル・インコーポレイテッドＮｏｖｕｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ，Ｉｎｃ． Ethoxylated surfactant
JP2017517761A (en) 2014-05-30 2017-06-29 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Method and apparatus for imaging large intact tissue samples
WO2017139501A1 (en) 2016-02-10 2017-08-17 The Board Of Trustees Of The Leland Stanford Junior University Rna fixation and detection in clarity-based hydrogel tissue
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997043314A2 (en) * 1996-05-16 1997-11-20 The Texas A & M University System Collagen binding protein compositions and methods of use
WO1998047541A1 (en) * 1997-04-24 1998-10-29 Nycomed Imaging As Contrast agents
WO2002047537A2 (en) * 2000-12-11 2002-06-20 Regents Of The University Of Michigan Compositions and methods for in situ and in vivo imaging of cells and tissues
US20030157113A1 (en) * 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
WO2005049005A1 (en) * 2003-11-14 2005-06-02 Ge Healthcare Limited Inhibitor imaging agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997043314A2 (en) * 1996-05-16 1997-11-20 The Texas A & M University System Collagen binding protein compositions and methods of use
WO1998047541A1 (en) * 1997-04-24 1998-10-29 Nycomed Imaging As Contrast agents
US20030157113A1 (en) * 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
WO2002047537A2 (en) * 2000-12-11 2002-06-20 Regents Of The University Of Michigan Compositions and methods for in situ and in vivo imaging of cells and tissues
WO2005049005A1 (en) * 2003-11-14 2005-06-02 Ge Healthcare Limited Inhibitor imaging agents

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "fluorochromes", INTERNET ARTICLE, 20 June 2004 (2004-06-20), XP002364123, Retrieved from the Internet <URL:www.biotech.iastate.edu/facilities/CELLHYB/Fluorochromes.doc> [retrieved on 200509] *
GOTWALS PHILIP J ET AL: "The alpha-1-beta-1 integrin is expressed during neointima formation in rat arteries and mediates collagen matrix reorganization", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 97, no. 11, June 1996 (1996-06-01), pages 2469 - 2477, XP002364122, ISSN: 0021-9738 *
KRAHN ET AL: "Fluorescently labeled collagen binding proteins allow specific visualization of collagen in tissues and live cell culture", ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 350, no. 2, 15 March 2006 (2006-03-15), pages 177 - 185, XP005312692, ISSN: 0003-2697 *
NYKVIST P ET AL: "DISTINCT RECOGNITION OF COLLAGEN SUBTYPES BY ALPHA1BETA1 AND ALPHA2BETA1 INTEGRINS", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 275, no. 11, 17 March 2000 (2000-03-17), pages 8255 - 8261, XP008051756, ISSN: 0021-9258 *
REULEN SANNE W A ET AL: "Protein-liposome conjugates using cysteine-lipids and native chemical ligation.", BIOCONJUGATE CHEMISTRY 2007 MAR-APR, vol. 18, no. 2, March 2007 (2007-03-01), pages 590 - 596, XP002434215, ISSN: 1043-1802 *

Also Published As

Publication number Publication date
WO2007030012A2 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
CY1124802T1 (en) SCLEROSTEIN BINDING FACTORS
WO2007030012A3 (en) Extracellular matrix imaging
DE602006013099D1 (en) COMPOSITION FOR TISSUE CARE
WO2008066752A8 (en) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
WO2007084264A3 (en) Methods for myocardial imaging
ATE520981T1 (en) DIAGNOSIS AND MONITORING OF DISEASES
WO2008020827A3 (en) Altered polypeptides, immunoconjugates thereof, and methods related thereto
CO6710903A2 (en) An antibody that specifically recognizes and binds with a phospho-epitope in the mammalian tau protein or in one of its fragments and a composition comprising the same
EA200200530A1 (en) HETEROCYCLIC SUBSTITUTED PYRAZOLONES
EA200701634A1 (en) ADDITIVES TO MEANS FOR WASHING THE BODY
WO2006122825A3 (en) Single domain vhh antibodies against von willebrand factor
MX348432B (en) Sclerostin epitopes.
PL378566A1 (en) Ligands for tgf-beta binding proteins and uses thereof
EA200701528A1 (en) NEW NUTRITSEVTIKY COMPOSITIONS
WO2009143519A3 (en) Biomarkers for myocardial ischemia
WO2009120995A3 (en) Collagen-binding synthetic peptidoglycans, preparation, and methods of use
WO2009109457A3 (en) Composition for dyeing keratin fibres comprising at least one direct dye comprising a disulphide/protected-thiol function and at least one siliceous compound comprising a thiol function and method using the composition
BRPI0414008B8 (en) compounds that bind to a thrombopoietin receptor, compositions and in vitro methods for activating a thrombopoietin receptor in a cell
ATE520025T1 (en) TEST FOR PARKINSON&#39;S DISEASE THERAPEUTICS
ATE459600T1 (en) SUBSTITUTED PYRROLIDINE-2-ONE
WO2013116668A3 (en) Diagnostic peptides for lyme disease
WO2007059300A3 (en) Anti-alk antagonist and agonist antibodies and uses thereof
WO2007039124A3 (en) Compositions comprising colostrum and hyaluronic acid for the treatment of vaginal dryness
MX2007011411A (en) Rage/diaphanous interaction and related compositions and methods.
NO20074528L (en) Substituted pyrroles, compositions, processes for the preparation and use of the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06783963

Country of ref document: EP

Kind code of ref document: A2